华丽家族股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600503 证券简称：华丽家族 公告编号：2025-024 (一)股东大会类型和届次 2025年第一次临时股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 29 日 至2025 年 8 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 一、 召开会议的基本情况 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 8 月 29 日 14 点 30 分 召开地点：上海市松 ...

证券代码：600503 证券简称：华丽家族 公告编号：临2025－023 华丽家族股份有限公司 公司拟于 2025 年 8 月 29 日 14:30 在上海市松江区石湖荡镇三新公路 207 号会议室 召开 2025 年第一次临时股东大会。 详见公司于上交所网站（www.sse.com.cn）及指定媒体披露的《华丽家族股份有限 公司关于召开 2025 年第一次临时股东大会的通知》（公告编号：2025-024）。 （表决结果：8 票同意，0 票反对，0 票弃权） 第七届董事会第三十九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 华丽家族股份有限公司（以下简称 "公司"）第七届董事会第三十九次会议于2025 年8月13日通过现场会议结合通讯表决的方式召开。会议通知于2025年8月8日以书面方 式送达全体董事。会议由董事长王伟林先生主持，会议应参加表决董事8人，实际参加 表决董事8人，公司高级管理人员列席了会议。本次会议的召集、召开及表决程序符合 《公司法》《公司章程》及《公司董事会议事规则》等有关规定。经与会董事审 ...

Group 1 - Multiple listed companies have announced plans to diversify into innovative pharmaceuticals this year, with Huayi Family planning to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. [1] - Shenlian Biopharmaceutical aims to expand from its existing animal vaccine business into the human innovative drug sector through acquisitions, having previously announced a 60 million yuan investment to acquire a 20.48% stake in Yangzhou Shizhiyuan Biotechnology Co., Ltd. [1][2] - The Chinese innovative drug market is experiencing rapid growth, with 43 innovative drugs approved in the first half of the year, a 59% year-on-year increase, and a projected total of 48 approvals for 2024 [2][3] Group 2 - Companies like Shenlian Biopharmaceutical are not only focused on financial returns but also on business synergies, leveraging their expertise in animal vaccines to enter the human drug market [3] - Huayi Family's investment in innovative drugs is seen as a strategic financial move, aiming for reasonable returns while exploring opportunities in emerging industries [2][3] - Traditional companies in mature industries are seeking new profit growth points through cross-industry diversification, which can aid in their transformation [3]

Investment Rating - The industry rating is optimistic, expecting overall returns to exceed the CSI 300 index by more than 5% in the next six months [11]. Core Insights - The report highlights that the real estate sector is experiencing a positive market trend, with the Shanghai Composite Index and Shenzhen Composite Index rising by 0.34% and 1.42% respectively on August 11, 2025. The Shenwan Real Estate Index increased by 1.24% [3]. - Specific developments include the planning adjustments in Shenzhen's Guangming District, which involve four residential land plots with varying land areas and floor area ratios [5]. - Guangzhou's state-owned enterprise, Zhujiang Real Estate, has initiated a price guarantee action for seven projects, promising to compensate buyers for price differences until the end of the year [6]. Market Performance - The top five performing stocks in the real estate sector include Shen Property A, Wantong Development, Tianbao Construction, Fuxing Shares, and Jintou City Development, with respective increases of 10.01%, 9.96%, 6.65%, 6.41%, and 6.01%. Conversely, the largest declines were seen in Rongfeng Holdings, Yatong Shares, Huali Family, Guangming Real Estate, and Shangshi Development, with decreases of -4.81%, -2.92%, -1.70%, -1.11%, and -1.04% [4]. Company Announcements - Huazhong City Holdings announced a suspension of trading due to a court-ordered liquidation [9]. - Zhuhai Huafa Industrial Co., Ltd. adjusted the coupon rate of its corporate bonds from 3.90% to 2.30%, with a total issuance of 2 billion yuan and a maturity of five years [9]. Industry News - The Shenzhen Intermediate People's Court announced the auction of the Shenzhen Huangting Plaza, with an estimated value of 4.361 billion yuan and a starting price of approximately 3.053 billion yuan [8].

Group 1 - Huayi Family Co., Ltd. plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement at a price of 4.75 yuan per share, acquiring no more than 63.157895 million shares [2] - After the investment, Huayi Family is expected to hold between 5% and 8.09% of Haihe Pharmaceutical's shares, with its controlling shareholder holding approximately 11.54% of Haihe Pharmaceutical's shares [2] - Haihe Pharmaceutical, established in 2011, focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already commercialized and five in clinical research [2] Group 2 - The investment is seen as a strategic financial investment based on the long-term development potential of innovative drugs, aiming to achieve reasonable financial returns while ensuring stable operations of Huayi Family's main business [3] - The innovative drug market has been rapidly developing, with many pharmaceutical companies achieving significant economic benefits through research and development [3] - Huayi Family aims to explore opportunities in emerging industries through this investment in Haihe Pharmaceutical [3]

Core Viewpoint - The company Huayi Family (600503.SH) plans to invest up to 300 million yuan in Haihe Pharmaceutical's share placement financing, aiming to acquire shares at a price of 4.75 yuan per share, totaling no more than 63.157895 million shares [1] Summary by Relevant Sections - Investment Details - The company intends to participate in Haihe Pharmaceutical's financing with a maximum investment of 300 million yuan [1] - The share price for the new shares is set at 4.75 yuan, allowing for the acquisition of up to 63.157895 million shares [1] - Ownership Implications - Post-investment, the company's ownership stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] - Strategic Objectives - The purpose of this capital increase is to ensure stable operations of the main business while seeking reasonable financial returns [1] - The investment also aims to explore opportunities in emerging industries and development prospects [1]

Group 1 - The company plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement, acquiring up to 63.157895 million new shares at a price of 4.75 yuan per share [1] - After the investment, the company's ownership stake in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] - Haihe Pharmaceutical focuses on the discovery, development, production, and commercialization of innovative drugs in the oncology field, with three products already launched in China and Japan, and five products in clinical research [1] Group 2 - This capital increase is a strategic financial investment reflecting the company's positive outlook on the long-term development potential of innovative drugs, aiming to ensure stable operations while seeking reasonable financial returns and exploring opportunities in emerging industries [2]

Core Viewpoint - The company plans to invest up to 300 million yuan in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. through a share placement, indicating a strategic financial investment in the long-term potential of innovative drugs [1][2] Group 1: Investment Details - The company intends to subscribe for no more than 63,157,895 new shares of Haihe Pharmaceutical at a price of 4.75 yuan per share [1] - Post-investment, the company's shareholding in Haihe Pharmaceutical is expected to be between 5% and 8.09% [1] Group 2: Target Company Overview - Haihe Pharmaceutical focuses on the discovery, development, production, and commercialization of innovative drugs, particularly in the oncology field [1] - The company has developed over ten research pipelines, with three products already launched in China and Japan, and five products currently in clinical research [1] - Haihe Pharmaceutical's pipelines target various cancers and chronic diseases, aiming to meet unmet clinical needs [1] Group 3: Strategic Intent - The investment is aimed at ensuring stable operations of the main business while seeking reasonable financial returns and exploring opportunities in emerging industries [2]

Group 1 - The company announced that its 38th meeting of the 7th board of directors was held on August 10, 2025, through a combination of on-site and communication voting [2] - The meeting reviewed the proposal regarding cash capital increase in Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. and related transactions [2]

Core Viewpoint - The audit report for Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. indicates that the financial statements fairly reflect the company's financial position and operating results for the periods ending December 31, 2024, and February 28, 2025, in accordance with accounting standards [3][4]. Financial Performance - The company's operating revenue for the year 2024 and the first two months of 2025 was reported at RMB 32,267.25 million, with growth rates of 80.89% and 89.24% respectively [4][5]. Audit Opinion - The audit firm, Zhongxinghua Certified Public Accountants LLP, concluded that the financial statements are prepared in accordance with the relevant accounting standards and provide a true and fair view of the company's financial status [3][4]. Key Audit Matters - Revenue recognition was identified as a key audit matter due to its significance in the financial statements and the inherent risk of management manipulating revenue recognition to meet specific targets [4][5]. - The audit procedures included evaluating internal controls related to revenue recognition, sampling sales contracts, and verifying supporting documents such as invoices and payment receipts [5][6]. Management Responsibilities - The management of Haihe Pharmaceutical is responsible for preparing the financial statements in accordance with accounting standards and ensuring the effectiveness of internal controls to prevent material misstatements due to fraud or error [6][7]. Shareholder Structure - The company underwent several changes in its shareholder structure, with the latest registered capital amounting to RMB 718,243.65 million, reflecting the contributions from various investors [21][22].